MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'amylin'. Sat, 03 Sep 2011 02:09:29 +0100 http://www.medworm.com/index.php?rid=5118994&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FX-4k_OX50Ks%2F Top of the morning to you. And what a morning it is. A lovely sun is shining overhead and a cool breeze is wafting through the Pharmalot corporate campus. This calls for a celebratory cup of stimulation. Nonetheless, meetings and deadlines loom. So let us all get started. A few interesting items can be found below. Meanwhile, if you hear of anything interesting, drop us a line. Have a great day, everyone… FDA OKs Gilead And J&J Once-Daily HIV Pill (Reuters) Pfizer Pays First Compensation To Nigerian Trovan Victims (BBC) Vioxx Lawyers Get More Fees After Filing Objections (Bloomberg News) Pfizer To Shed 130 Jobs And Close Former King Plant (TriCities) FDA Sets Review Deadline For Amylin Diabetes Drug (Reuters) FDA Questions Adventrx Trial Run By CRO In Argentina (Outsourcing Phar... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5118994 Thu, 11 Aug 2011 11:53:50 +0100 5118994 http://www.medworm.com/index.php?rid=5097083&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNigM4gh7KXI%2F And so, another working week is about to come to an end. Not a moment too soon, yes? This is, of course, our signal to daydream about weekend plans. Our modest agenda includes golfing with our shortest of short people, catching up on some reading and taking at least one cozy nap. And you? How about a day at the beach? A night out with someone special? Or perhaps a shopping trip to stimulate what is left of the economy? Whatever you do, be safe and enjoy. Meanwhile, here is an assortment of tidbits. See you soon… Pharma Collaborations Are On The Rise (Nature Reviews Drug Discovery) Payers Will Want More Biosimilar Data Than FDA (Pharma Times) Cost Of Medicare Part D Drug Plan Is Dropping (The Los Angeles Times) Takeda And Amylin Pull The Plug On Obesity Drug (Bloomberg News) NICE Reje... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5097083 Fri, 05 Aug 2011 12:08:49 +0100 5097083 http://www.medworm.com/index.php?rid=4829304&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FMFHc1WKmzjk%2F Since 2002, Amylin Pharmaceuticals has worked closely with Eli Lilly to develop and market diabetes meds. Specifically, the two drugmakers sell the twice-a-day Byetta med and have been laboring to win approval for Bydureon, a once-weekly injectable that is designed to supplant the older drug. But like many partnerships, suspicision and mistrust often emerge and so Amylin has just filed a lawsuit in federal court charging Lilly with anticompetitive activity and breaching their “strategic alliance.” Why? This past January, Lilly signed a deal with Boehringer Ingelheim to jointly develop and sell several diabetes compounds that are in mid- and late-stage development, including a Boehringer oral diabetes agent known as linagliptin (read here). This has not sat well with Amylin, whi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4829304 Mon, 16 May 2011 13:43:16 +0100 4829304 http://www.medworm.com/index.php?rid=4715016&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FYiEPmFQ6yMo%2F And so another work week will soon draw to a close. This means, of course, the time has come to daydream about weekend plans. Our agenda includes spring cleaning, taking one of our short people to a soccer match and catching up on some sleep. What about you? Anything special planned? A walk in the park? Reaching out to an old friend? Maybe planning the rest of your life? Whatever you do, have a great time. Meanwhile, here are some tidbits. Catch you soon… EU Backs Boehringer Pradaxa Stroke Prevention Drug (Reuters) US Will Negotiate Medicare Drug Prices: Obama (Pharma Times) EU OKs Bydureon Diabetes Med From Lilly & Amylin (Reuters) Genzyme MS Drug Shows Promising Five-Year Results (Mass High Tech) Glaxo To Sell Plant And Eliminate 250 Jobs (Memphis Business Journal) Glaxo To Se... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4715016 Fri, 15 Apr 2011 11:33:47 +0100 4715016 http://www.medworm.com/index.php?rid=4606053&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FM9vyesqva3w%2F Top of the morning to you. A sunny day is unfolding here on the Pharmalot corporate campus where, once again, we are hustling the short people off to the school house. And then we will catch up on reading some interesting documents. What about you? Meetings and deadlines beckon? Of course. To help you along, here are some tidbits from around the world. Have a great day, everyone… Genzyme In Talks To Conduct R&D In Russia (Reuters) UK’s NICE Backs Simponi Rheumatoid Arthritis Med (Dow Jones) CMS Declines To Change Coverage For Anemia Meds (Reuters) ITC To Probe Lilly Infringement Claim (Indianapolis Business Journal) Pfizer Reaches Tax Deal With School District (LoHud) Ireland Plans Pharma Research Center (Irish Independent) CALPERS Ends Talks With Medco (Associated Press) ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4606053 Thu, 17 Mar 2011 11:53:34 +0100 4606053 http://www.medworm.com/index.php?rid=4575247&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F0Udf2nUwwkU%2F And so another working week will soon draw to a close. This, of course, means that the time has come to daydream about weekend plans. Our agenda is rather modest - we hope to do fun things with assorted short people, catch up on some sleep and read interesting documents about a big drugmaker (this can actually be relaxing). What about you? Will you cavort with a special someone? Run some errands? Make plans to escape somewhere? Whatever your fancy, be safe and enjoy. Meanwhile, here a few tidbits. See you soon… Merck Not Obligated To Accept Bid For Dutch Organon Unit (Dow Jones) Amgen Will Buy Pfizer Plant In Ireland (Bloomberg News) Arena Pharma Narrows Losses (Associated Press) Roche’s Accutane Caused Tragedy For An Actor (Bloomberg News) Dendreon Gets OK To Expand Provenge C... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4575247 Fri, 11 Mar 2011 12:37:29 +0100 4575247 http://www.medworm.com/index.php?rid=4545252&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FgKTyXRkHZp0%2F For those who wonder why drugmakers shy away from head-to-head studies, consider the plight of Amylin Pharmaceuticals, Eli Lilly and Alkermes. A newly released study shows their forthcoming Bydureon diabetes med - a once-weekly injectable that is designed to supplant the twice-a-day Byetta - failed to lower blood sugar as effectively as a rival drug, Novo Nordisk’s Victoza. The results are causing investors to pound Amylin stock - shares were down about 25 percent all morning - as some analysts now question the ability of the drugmakers to successfully win FDA approval for the med anytime soon. The agency, you may recall, last year requested more info on manufacturing and a risk mitigation plan. Meanwhile, Victoza has been available more than a year. The bottom line: Patients who too... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4545252 Thu, 03 Mar 2011 20:18:12 +0100 4545252 http://www.medworm.com/index.php?rid=4406036&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FQi1kO4OIQZc%2F Hello, everyone. And how are you today? Yet another pile of snow has descended on the Pharmalot corporate campus, where we have a shovel in one hand and a cup of stimulation in the other. Nonetheless, we will not be deterred from foraging for interesting news and assorted developments. And so here are a few tidbits to get us all started. Enjoy, and we hope your day goes well… AstraZeneca To Double Stock Buybacks Amid Drug Setbacks (Bloomberg News) Lilly Profit And Sales Beat Wall Street Forecasts (Reuters) Off-Label Prescribing To Children Is Widespread In Europe (PharmaTimes) FDA Denies Additional Indication For Glaxo’s Avodart (Reuters) Data Exclusivity Remains Hurdle To EU-India Free Trade Deal (Business Standard) Novartis Profit Falls And Vaccine Sales Slide (Bloomberg News... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4406036 Thu, 27 Jan 2011 12:56:53 +0100 4406036 http://www.medworm.com/index.php?rid=4285353&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fj_8GX6iXEFk%2F The holiday weekend may be in the offing, but the Pharmalot corporate campus is still humming. And why not? The world has not stopped spinning, after all, and there is always something interesting going on. So while you prepare for a celebration or simply slow down the usual pace, here are a few items to help you along. Meanwhile, we pass along holiday greetings and hope everyone has a chance to catch up on some fun things and enjoy life. See you soon… Cephalon Names Kevin Buchi As CEO (statement) Lundbeck Alcoholism Pill May Be A Goldmine (Bloomberg News) Novartis To Build Vaccine Plant In North Carolina (Raleigh News & Observer) FDA Reviews Safety Of Human Growth Hormone Drugs (Reuters) Pfizer And Bristol Bloodthiners Beats Sanofi Drug In Study (Bloomberg News) Massachusetts Award... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4285353 Thu, 23 Dec 2010 12:54:53 +0100 4285353 http://www.medworm.com/index.php?rid=4086516&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FOaRufoPftmM%2F The surprising news released last night that the FDA has refused to approve the Bydureon diabetes drug - which involves a three-way partnership between Eli Lilly, Alkermes and Amylin Pharmaceutical - adds tremendous pressure on the big drugmaker to pursue some kind of deal to bolster its anemic pipeline. An acquistion would be the likeliest approach, but Lilly may be more vulnerable bait itself. The initial reaction among some Wall Street wags is that Lilly may want to take a stake in, if not acquire Amylin, given that so much has already been invested in Bydureon, which the FDA rejected over concerns that cardiac abnormalities (look here). The med, which is a once-weekly version of Byetta, was already delayed due to cancer risks (see this), but Lilly has a long-standing diabetes franchise... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4086516 Wed, 20 Oct 2010 13:10:40 +0100 4086516 http://www.medworm.com/index.php?rid=4086518&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FijNS9kKsegA%2F Hello, everyone, nice to see you again. Another shiny day is emerging here on the Pharmalot corporate campus, where we are hustling to deliver one of the short people to the local schoolhouse. Busy, busy, busy. Meanwhile, those meetings and deadlines loom. We know you relate. So here are a few interesting items to help you along. Have a wonderful day and stay in touch… Pfizer Pays $240M For Stake In Brazil’s Teuto (Reuters) Vioxx Lawyers Who Led Settlement Will Get $315M (Bloomberg News) Boehringer’s Pradaxa Bloodthinner Wins FDA Approval (Reuters) Amylin’s Diabetes Drug Debacle (TheStreet) McKesson To Pay $15M To Connecticut For Inflating Prices (CTNow) Sanofi Wins $442M Judgment Over Plavix Patent (Bloomberg News) Anti-Counterfeiting Effort Nabs 1M Pills (InPharma... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4086518 Wed, 20 Oct 2010 11:41:18 +0100 4086518 http://www.medworm.com/index.php?rid=3699708&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FQdlbcRhrvF8%2F And so another work week will soon draw to a close. Not a moment to soon, eh? Well, hopefully, your week has been productive and rewarding. Now, though, it is time to consider other activities. Have any interesting weekend plans? We hope to catch up on sundry chores, a bit of reading and promenade with the official Pharmalot mascots. Whatever you do, have an enjoyable time. See you soon… Massachusetts May Repeal Ban On Gifts To Doctors (Boston Globe) Merck Wins EMA Support For Antpsychotic (Reuters) Sanofi Signs $375M Deal With Metabolex (PharmaTimes) The Qnexa Diet Pill Goes To An FDA Panel (Minynaville) Shire Gaucher Disease Drug Wins EMA Backing (Reuters) Glaxo Explores ‘Printed’ Pill Technology (Dow Jones) Novartis’ Gleevec Fails To Win UK Backing For GIST Patie... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3699708 Fri, 25 Jun 2010 11:32:45 +0100 3699708 http://www.medworm.com/index.php?rid=3683874&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fs0oRUJccZDM%2F Welcome back. We hope your weekend was restful and invigorating. Now, of course, the routine returns as those meetings and deadlines beckon. For our part, we will break later today to watch one of the short people accept a well-deserved diploma. Excelsior, as they say. Meanwhile, enjoy a cup of stimulation and survey some news of the world. Hope your day is a good one… Cannabis Drug Goes On Sale In The UK (The Wall Street Journal) Lilly Trims Public Relations Staff (Indiana Business Journal) Valeant Pharma And Biovail Agree To Merge (Bloomberg News) Sigma Pharma Chairman Resigns (Sydney Morning Herald) NJ Budget Cut Proposals Will Hurt Biotechs (NJSpotlight) Medco And Celesio Form European Joint Venture (Bloomberg News) Amylin Lays Off 60 Employees (San Diego Union-Tribune) Medicis P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3683874 Mon, 21 Jun 2010 11:34:44 +0100 3683874 http://www.medworm.com/index.php?rid=3542873&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fdtv4OBHXOuY%2F Once again, another working week will soon draw to a close. And so the weekend agenda calls for a smattering of activities - taking the Pharmalot mascot for a constitutional, bike riding with one of the short people and watching another on the lacrosse field. And you? Whatever you plan, we hope you have a good time. And of course, do not forget mom. Have a great time… FDA To Review Lilly’s Byetta In Six Months (Reuters) Lilly To Cut 200 Sales & Marketing Jobs (Indianapolis Star) InVentiv To Be Bought For $900M By Thomas Lee (Wall Street Journal) Bayer Wins FDA Approval For New Type Of Contraceptive (Bloomberg News) Genzyme Plans $2B Buyback, May Sell Units (Associated Press) Australia Agrees To $2B In Price Cuts (PharmaTimes) photo thx to tipiro on Flickr creative commons ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3542873 Fri, 07 May 2010 11:37:14 +0100 3542873 http://www.medworm.com/index.php?rid=3460396&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F9dOm2DDD8d0%2F This is not good news for Eli Lilly or its partner, Amylin Pharmaceuticals, which are counting on their once-weekly version of the Byetta diabetes treatment to become a much-needed blockbuster. A Jan. 25 memo written by an FDA official notes that data suggests the med appears to “give a similar signal” as cancers seen rat studies of Novo Nordisk’s competing Victoza. Victoza, you may recall, was approved in January after nearly a year’s delay over safety concerns. At the time, the agency noted that thyroid tumors may be common with all extended-release diabetes drugs in a group of meds known as GLP-1 analogs, which includes Byetta and Victoza. Last month, the FDA delayed approving the new Byetta and sought more info on labeling and a risk-management plan, although ne... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3460396 Mon, 12 Apr 2010 11:54:26 +0100 3460396 http://www.medworm.com/index.php?rid=3370614&cid=t_110625_134_f&fid=35187&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDiabetesDaily%2F%7E3%2F1bcCGQlZK70%2Ffood-issues-type-1-diabetes.php My latest "Viewpoints" article is up over at dLife.This month I'm talking about something that I bet many of us struggle with.  I know that it is a real battle for me, and it is starting to make sense why.  The topic is also starting to pop up more and more in some of the media blurbs and articles I've seen recently.I knew weeks before I wrote my viewpoints article what I wanted to write about.  The basic concept is that being a type 1 diabetic, there are a few factors contributing to the problems I have with food.  Growing up on R and NPH insulins, I had to eat at certain times, whether I was hungry or not.  Because of this my natural "hungry/satisfied" wires are all messed up.Even on a pump and using just Humalog/Novolog, we still often have to override our natur... Diabetes Daily blogs http://www.medworm.com/rss/comments.php?id=3370614 Mon, 15 Mar 2010 17:10:55 +0100 3370614 http://www.medworm.com/index.php?rid=3366430&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FzZvPAeo5eqw%2F Welcome back, everyone. We hope your weekend was pleasant. We had a soggy time here on the Pharmalot corporate campus, where the rains overwhelmed us. Now, though, we are drying out and brewing a cup of stimulation to jumpstart the day. To help you along, we have found a few interesting items. Stay in touch… FDA Delays Approval Of Lilly, Amylin Diabetes Drug (Reuters) Pet Owners Sue Over Flea Meds (The Morning Call) Abbott’s TriCor Fails To Beat Placebo (Forbes) Merck Urged To Lower Isentress Price (SouthFloridaGayNews) Court Rules Against Autism Vaccine Claims (Reuters) Genetix Gets $35M For Gene Therapy Work (Xconomy) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3366430 Mon, 15 Mar 2010 11:58:57 +0100 3366430 http://www.medworm.com/index.php?rid=3172202&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F5x3gAtaxrKg%2F Earlier this week, the FDA posted warning letters on its site to four drugmakers - Lilly, Bayer, Amylin Pharmaceuticals and Cephalon - for making inaccurate or incomplete statements while promoting their drugs. Amylin, for instance, was tagged because its reps made remarks that Byetta can be used as a stand-alone therapy, which was before the drug received that approval. Bayer was chastised for suggesting its Mirena contraceptive women help would feel more romantic or intimate when, in fact, the side effects indicate the opposite may occur. A dosing card for Cephalon’s Treanda, which treats chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, minimized risk and a Lilly promotional piece for its Cymbalta antidepressant minimized risk and overstated efficacy. As The Pink She... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3172202 Thu, 14 Jan 2010 12:02:03 +0100 3172202 http://www.medworm.com/index.php?rid=3167447&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FkUGyOqgkCw8%2F Hello, everyone. For those struggling with the mid-week blues, we are reminded of that uplifting comment from the Morning Mayor: ‘Every brand new day should be unwrapped like a precious gift.’ So keep that in mind as you attempt to attack those meetings and projects. You will prevail. Meanwhile, we will arm ourselves with a cup of stimulation. Here’s to a good day… Novo Starts Testing Victoza Diabetes Pill (Reuters) FDA Send Warnings To Bayer, Lilly, Cephalon & Amylin (Associated Press) Will Novartis Raise Its Bid For Alcon? (Reuters) Charles River Labs To Cut 300 Jobs (OutsourcingPharma) WHO To Review Swine Flu Response (Bloomberg News) Coffee thanks to chichcacha Flickr Common Creative (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3167447 Wed, 13 Jan 2010 13:23:06 +0100 3167447 http://www.medworm.com/index.php?rid=3119062&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fys_xmHL3T3A%2F File this under sticking point. The agency wants Amylin Pharmaceuticals to run more studies of its Type 2 diabetes drug, which was approved two months ago as a stand-alone treatment, due to safety concerns over pancreatitis, according to an investor note issued yesterday by Citigroup analyst Yaron Werber. At the time of the Oct. 30 approval, Amylin indicated prescribing info would warn about pancreatitis in patients with severe kidney disease. You may recall the twice-daily injectable drug was linked to six deaths last year (see here), which hurt sales. However, the Amylin statement didn’t mention additional studies. Werber wrote that he obtained a copy of the FDA’s approval letter and the agency considers post-marketing reports of acute pancreatitis, acute renal failure and thyr... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3119062 Thu, 24 Dec 2009 13:10:33 +0100 3119062 http://www.medworm.com/index.php?rid=2950995&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FGLpICeeuy88%2F Welcome back. We hope your weekend was fun. After all, there was Halloween and the World Series for baseball fans. And there was plenty of opportunity to get some exercise raking leaves, at least for those who live in the US Northeast. Now, though, another week beckons. And so as you prepare for those meetings and deadlines, here are a few items to help you along. Have a nice day everyone… Will Pfizer Buy Protalix? (Globes) Amylin And Takeda To Develop Obesity Drugs (Reuters) Dendreon Seeks FDA Approval For Provenge Vaccine (Reuters) Human Genome Sciences’ Lupus Drug Cuts Symptoms (Bloomberg) Schering-Plough Reports Hepatitis C Drug Results (Associated Press) Vertex Pitches Its Hepatitis C Drug (The Boston Globe) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2950995 Mon, 02 Nov 2009 12:21:12 +0100 2950995 http://www.medworm.com/index.php?rid=2950996&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLRtHKZAGaF8%2F Such a busy pharma world and so little time to keep up, yes? Like you, we always poke around for items of interest, and so we thought we would point out a few you may enjoy from the past week. Think of it as a little bit of catching up. Meanwhile, we hope your weekend is enjoyable and look forward to seeing you again tomorrow… Amylin Pharmaceuticals and Lilly announced Byetta was approved as a stand-alone med, along with diet and exercise, for type 2 diabetes. Until now, the drug was approved only for patients taking other common diabetes treatments. Tucked away in their statement, they disclosed safety warnings relating to pancreatitis risks and use by patients with severe kidney disease. Six patients taking Byetta died in August 2008 from pancreatitis, prompting an FDA safety alert. P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2950996 Sun, 01 Nov 2009 18:44:39 +0100 2950996 http://www.medworm.com/index.php?rid=2021729&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F478500834%2F The agency now appears likely to extends its review of the injectable diabetes med, which Lilly and Amylin Pharmaceuticals want approved as a stand-alone treatment, into next year. The FDA, however, apparently did not request additional studies, but is reviewing prescribing info and wants safety language revised, according to a statement from the drugmakers. Byetta has caused all sorts of turmoil for Lilly and Amylin this year, thanks to reports of pancreatitis. A total of four deaths were reported this past summer (look here), and a subsequent slowdown in sales contributed to a 25 percent staff reduction last month (see here). Amylin and Lilly are also developing a long-acting version of Byetta known as exenatide LAR, although its fate is unclear due to Byetta’s safety concerns. An... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2021729 Mon, 08 Dec 2008 14:32:32 +0100 2021729 http://www.medworm.com/index.php?rid=1981288&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F460722285%2F The global economic crisis has cut funding for biotechs to the lowest level in a decade, triggering bankruptcies and threatening development of drugs based on biomedical breakthroughs, Bloomberg News writes. In the past month, at least five biotechs filed for bankruptcy. Those at highest risk have experimental compounds moving into costly human research. The amount raised this year by biotechs fell by $9.7 billion through September, or 54 percent, compared with the same period in 2007, according to Burrill & Company, a life sciences investment bank. That may mean work on dozens of potential treatments will stall or die as workers are fired and early research projects are shelves, Bloomberg writes. “I’m looking down the barrel of a gun,” says Tom Mathers, ceo at Peptimmune, a p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1981288 Fri, 21 Nov 2008 12:47:36 +0100 1981288 http://www.medworm.com/index.php?rid=1947482&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F449006769%2F The 25 percent staff reduction, which follows sluggish sales of its flagship Byetta diabetes med, is designed to save more than $100 million next year. After the dust clear, Amylin will have 1,800 employees. You may recall that, last summer, there were six deaths among patients with pancreatitis who took their Byetta diabetes drug (back story). “The purpose of the reorganization is to really put us in a stronger position as a company to execute our business plan and become cash flow positive by 2010,” Amylin Pharmaceuticals ceo Daniel Bradbury says in a statement. The drugmaker vows to increase sales of Byetta and its Symlin med for Type 1 diabetes, and bring to market a once-a-week version of Byetta, called exenatide LAR. The FDA recently rejected study data that was meant to sho... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1947482 Tue, 11 Nov 2008 01:25:35 +0100 1947482 http://www.medworm.com/index.php?rid=1933423&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F442409558%2F That’s because FDA approval for its much-anticipated exenatide LAR diabetes drug could be delayed, according to a filing with the Securities and Exchange Commission. The agency rejected study data that was meant to show that exenatide LAR batches made by its partner, Alkermes, were equivalent to batches made at Amylin’s own facility in Ohio. The upshot is that, if Amylin has to conduct another study, it would likely delay plans for FDA approval by the middle of 2009. Amylin continuing discussions with the FDA. Not surprisingly, the disclosure hammered stocks for both companies, since exenatide is supposed to be the follow-up for Byetta. The bad news follows reports in August of six deaths in patients taking its Byetta diabetes med, although the deaths have not been directly lin... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1933423 Tue, 04 Nov 2008 19:18:19 +0100 1933423 http://www.medworm.com/index.php?rid=1917969&cid=t_110625_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F10%2Fmy-life-as-a-compliance-analyst-the-case-for-pharma-reps.html I met Alexis at the recent BDI luncheon for women with Type 1 diabetes. She seemed bubbly and smart, and I felt an instant connection.  When I discovered her job title was “Compliance Analyst,” I just had to hear more about that.  Turns out it’s not quite what you think, but fascinating nevertheless. A Guest Post [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=1917969 Wed, 29 Oct 2008 14:14:51 +0100 1917969 http://www.medworm.com/index.php?rid=1791608&cid=t_110625_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F09%2Fwill-byetta-bounce.html “Exenatide LAR is not only more convenient than Byetta and liraglutide, but it may be the most potent diabetic agent in terms of (blood glucose) reduction.”More (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1791608 Sun, 14 Sep 2008 13:53:00 +0100 1791608 http://www.medworm.com/index.php?rid=1782895&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F387776565%2F The troubled Byetta diabetes drug, which is marketed by Lilly and Amylin Pharmaceuticals, worked better than Merck’s Januvia in trials that measured blood sugar levels after meals in 61 patients who tried each drug for two weeks. Those taking Byetta had lower blood-sugar levels and ate less food than when they used Januvia, according to the drugmakers, which expect to release the company-sponsored study today at a meeting of the European Association for the Study of Diabetes in Rome. The results contrast with the dismal news released last month that six patients taking Byetta died of pancreatitis. Amylin maintained there was no evidence to link the drug to the deaths, but Wall Street and doctors have been wary (back story). “There has been some confusion in the marketplace ab... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1782895 Tue, 09 Sep 2008 15:55:49 +0100 1782895 http://www.medworm.com/index.php?rid=1739108&cid=t_110625_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F08%2Famylin-byetta-more-bad-news.html Story (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1739108 Wed, 27 Aug 2008 15:39:00 +0100 1739108 http://www.medworm.com/index.php?rid=1739273&cid=t_110625_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F08%2Fmore-exposure-of-trouble-at-fda.html No doubt, you have read about the brew ha ha over the type 2 diabetes medicine Byetta being linked to pancreatitis which lead to the death of a few (I believe around 6 cases at the last count, out of over a million prescriptions worldwide). In fact, last night at 5:00 PM, Amylin Pharmaceuticals and Eli Lilly and Company (who jointly market Byetta, known generically as exenatide) held a conference call intended to do damage control on the issue. Lilly, in particular, depends heavily on Amylin's Byetta to fuel its sagging diabetes business. The company continues to lose market share in insulin to rivals Novo Nordisk and Sanofi Aventis largely because Lilly is the only one of the big 3 insulin makers who offers only a rapid-acting insulin analogue, but in order to win business from insurers a... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1739273 Wed, 27 Aug 2008 12:50:00 +0100 1739273 http://www.medworm.com/index.php?rid=1734249&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F375570999%2F Lilly and Amylin Pharmaceuticals are saying there have been four deaths among patients with pancreatitis who took their Byetta diabetes drug, in addition to the two deaths reported last week by the FDA. Amylin says the four cases were not captured by the FDA, which received six reports of patients who developed hemorrhagic or necrotizing pancreatitis that required hospitalization. Two of those died. The additional four cases reported today did not involve patients with the necrotizing form of the disease, which affects 15 percent to 20 percent of patients with inflammation of the pancreas. “It appears the FDA focused on necrotizing and hemorrhagic pancreatitis, whereas these other four cases only had pancreatitis in their history,” Orville Kolterman, Amylin’s senior vice... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1734249 Tue, 26 Aug 2008 21:45:43 +0100 1734249 http://www.medworm.com/index.php?rid=1734254&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F375207000%2F The drugmaker has scheduled a teleconference call for 5 pm EST today about last week’s FDA advisory on Byetta, the diabetes med that is marketed with Amylin Pharmaceuticals. The agency found that deaths continue to be reported despite earlier government warnings. The latest - six new reports were received of patients developing a dangerous form of pancreatitis, with two actually dying. Participating in the call will be Don Therasse, Lilly’s vp of global patient safety, Dan Bradbury, Amylin’s ceo and president, and Orville Kolterman, Amylin’s senior vp of R&D. However, the direction the call will take was not disclosed, prompting Catherine Arnold of Credit Suisse to write in an investor note this morning that the move may cause apprehension among investors. Why? Bye... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1734254 Tue, 26 Aug 2008 13:14:22 +0100 1734254 http://www.medworm.com/index.php?rid=1720336&cid=t_110625_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F08%2Famylin-byetta-pain-in-gut.html Story (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1720336 Wed, 20 Aug 2008 12:31:00 +0100 1720336 http://www.medworm.com/index.php?rid=1714166&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F368372415%2F The FDA is working on a stronger label for the widely used diabetes drug, which is marketed by Lilly and Amylin Pharmaceuticals after deaths continue to be reported despite earlier government warnings. Six new new reports were received of patients developing a dangerous form of pancreatitis while taking Byetta. Two patients died and four were recovering, the Associated Press reports. The drugmakers said in a statement that patients taking Byetta have shown “very rare case reports of pancreatitis with complications or with a fatal outcome.” They added that diabetes patients are already at increased risk of pancreatitis compared with healthy patients. The FDA announcement updated an October alert about 30 reports of Byetta patients developing the ailment. Regulators stressed that... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1714166 Mon, 18 Aug 2008 19:27:55 +0100 1714166 http://www.medworm.com/index.php?rid=1700805&cid=t_110625_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F08%2Fare-amylins-days-really-numbered.html This isn't exactly new news, but back in June, the Indianapolis Star reported that corporate raider Carl Icahn had acquired a $200 million stake in Amylin Pharmaceuticals, Inc., the San Diego-based biotechnology company perhaps best known for its stake in the blockbuster type 2 diabetes drug Byetta. Amylin is also responsible for the company's namesake drug sold under the brand-name Symlin, which is less a drug and more a biosynthtic analogue of the hormone amylin, a hormone which is completely absent in patients with type 1 diabetes.The long story short is patients have no need to be concerned about Icahn's intentions anyway, as even if Icahn forces Amylin, Inc. into the arms of partner Eli Lilly and Company, their product line will most certainly not disappear. Should investors in Amylin... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1700805 Tue, 12 Aug 2008 13:15:00 +0100 1700805 http://www.medworm.com/index.php?rid=1675139&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F352692430%2F That’s the speculation now that Roche has made an offer for the chunk of Genentech not under its control and Bristol-Myers Squibb is trying the same thing with ImClone Systems. So now the betting is that Lilly would bid for Amylin, its partner for the Byetta diabetes drug and a long-acting release version that is being developd. “While two large pharma companies have now moved to acquire their commercial partners (in which they already held shares), it is now reasonable to wonder whether there will be a rash of such deals, and who will be next,” Deutsche Bank analyst Barbara Ryan writes in an investor note. “While it is certainly possible and plausible that Lilly would buy Amylin…our assessment is that it is unlikely to be a near-term event, if it were to happ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1675139 Fri, 01 Aug 2008 15:04:42 +0100 1675139 http://www.medworm.com/index.php?rid=1642829&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F342446770%2F Who said the summer is a slow season? Yesterday brought us the news that doctors may have yet another reason to wonder about Vytorin. And many Roche employees in New Jersey must now consider finding new jobs or, in some cases, moving to California to work for Genentech. What will today bring? We can only stay tuned. Hope this helps you get started… Ranbaxy Says UK Court Quashes Fraud Prosecution (Bloomberg News) FDA Employees Should Be Stationed Overseas Next Year (Bloomberg News) Merck Withholds Forecasts After Vytorin Study (Yahoo/Reuters) J&J’s Topamax Raised Birth Defect In Epilepsy Study (Bloomberg News) Amylin Pharmaceuticals Posts Wider Loss (Yahoo/Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1642829 Tue, 22 Jul 2008 11:06:01 +0100 1642829 http://www.medworm.com/index.php?rid=1596411&cid=t_110625_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2008%2F07%2Fnovel-approach-to-communicating-with.html That's the title of a Pharma Marketing News article I wrote some time ago about "a patent-pending technology" developed by a company called MagicMedia Communications. It offers a novel way for pharmaceutical sales representatives to "talk" to a doctor…even when face-to-face discussion is not possible!I didn't give the secret away in the summary of the article, but I can now tell you that it was a "talking greeting card." You've probably seen Hallmark Cards TV ads that show someone recording a personalized audio message on a card they will send to a friend or relative. Cute!That was the idea behind what MagicMedia was offering to pharmaceutical companies. The idea was to leave behind a card with a sales message when the physician was too busy to see the rep. The original idea was to allow... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=1596411 Tue, 08 Jul 2008 12:11:00 +0100 1596411 http://www.medworm.com/index.php?rid=1522441&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F312998691%2F The famed corporate raider recently bought $200 million worth of stock in Amylin Pharmaceuticals, which is one of Lilly’s most critical partners, and the move raises questions about whether Icahn plans to push Amylin for a shakeup or a takeover, and whether that would threaten Lilly’s interests in the Byetta diabetes drug, The Indianapolis Star writes. On the other hand, pressure from Icahn could create an opportunity for Lilly to buy out its partner and get full control of the diabetes med, which generated $650 million in sales last year. But some analysts say it could become a multibillion-dollar blockbuster if a new long-acting version in clinical trials wins approval. Recently released clinical data seemed to raise its prospects, the paper notes. Icahn has disclosed no plan... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1522441 Mon, 16 Jun 2008 12:37:45 +0100 1522441 http://www.medworm.com/index.php?rid=1502737&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F308273085%2F There was an 8 percent drop on Friday after Novo Nordisk presented data showing its once-a-day experimental med outperformed Amylin’s twice-a-day, Byetta flagship. Now, Amylin sunk another 10 percent after Roche released data at the American Diabetes Association meeting that poses yet another threat to both Byetta and a longer-lasting, follow-up drug. Both the Novo and Roche drugs are “viable” candidates, according to Cowen analyst Phil Nadeau, the Associated Press writes. As a result, competition will increase in the GLP-1 class of diabetes meds that stimulate the release of insulin only when glucose levels become too high. They also lead to modest weight loss, which is seen as an advantage over drugs. But Jim Birchenough of Friedman Billings Ramsey issued an investor no... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1502737 Mon, 09 Jun 2008 20:17:26 +0100 1502737 http://www.medworm.com/index.php?rid=1389202&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F274655473%2F Lilly posted lower-than-expected quarterly earnings, as disappointing sales of its Byetta diabetes drug overshadowed growing demand for its older diabetes treatments and Cialis impotence drug. Net income was $1.06 billion, or 97 cents a share, compared with $508.7 million, or 47 cents, a year earlier. Excluding special items, Lilly earned 92 cents per share, below analysts estimates of 96 cents, according to Reuters. Revenue grew 14 percent to $4.81 billion, in line with forecasts, but sales would have risen only 9 percent if not for favorable foreign exchange factors. Global sales of the Byetta injectable diabetes drug rose 15 percent to $169 million. The drug is sold in partnership with Amylin, which says wholesalers cut back on purchases. Here is the Lilly statement and the Amylin state... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1389202 Mon, 21 Apr 2008 12:04:01 +0100 1389202 http://www.medworm.com/index.php?rid=1286448&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F247454539%2F The quest to find the magic diet pill knows no limits. Of course, the path is littered with failures in the form of embarassing side effects, heart and lung damage, suicides, lawsuits and, more recently, FDA rejection. Think fen-phen. Think Acomplia. Think Xenical and orange undies. But the obsession with looking slimmer and the adverse consequences brought on by excess weight - high cholesterol, high blood pressure, diabetes - make obesity too compelling - translation: potentially profitable - to ignore. And so BusinessWeek takes a look at three of the more interesting prospects that are currently intriguing researchers, investors and, soon enough, regulators. Whether any will succeed, well, don’t give up your diet yet. Take Vivus, a small company that is testing Qnexa, a mix of phe... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1286448 Fri, 07 Mar 2008 16:10:48 +0100 1286448 http://www.medworm.com/index.php?rid=1068797&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F194961311%2F In case you missed it, this has been quite a year for high-profile safety news. And so FiercePharma has compiled a list for the cocktail set, who want to keep track of such things. These are the 10 biggest drugs that were withdrawn or were issued new warnings by the FDA this year. The drugs are ranked by 2006 worldwide sales, which explains why such headline grabbers as Bayer’s Trasylol doesn’t appear - sales were already tanking on bad news. 1. Antidepressants - Various companies 2. Epogen/Aranesp - Amgen 3. Zyprexa - Lilly 4. Avandia - Glaxo 5. Actos - Takeda 6. Provigil - Cephalon 7. Zelnorm - Novartis 8. Byetta - Amylin 9. Xolair - Genentech 10. Fentora - Cephalon Source: FiercePharma Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1068797 Tue, 04 Dec 2007 14:15:23 +0100 1068797 http://www.medworm.com/index.php?rid=1010642&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F181073440%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Mylan appointed Joe Haggerty senior vp and global general counsel; Peak International named Keith Bladen to its board of directors; Amylin Pharmaceuticals elected Adrian Adams to its board of directors; CryoLife hired Scott Capps as vice president, clinical research; Anthera Pharmaceuticals appointed Donald Santel to its board of directors; Genelabs Technologies names Frederick Driscoll as cfo; OncoMed appointed William Waddill senior vice president and cfo; Immunos... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1010642 Wed, 07 Nov 2007 12:51:32 +0100 1010642 http://www.medworm.com/index.php?rid=957304&cid=t_110625_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2007%2F10%2Ffda-warns-of-risk-for-pancreatitis-with.html In a sign that the FDA does not want to see a repeat of the events that occurred regarding the type 2 diabetes drug Avandia requiring more label warnings due to risk of cardiovascular events associated with that drug, the U.S. Food and Drug Administration has called attention to something which appears to be a tiny risk associated with another type 2 diabetes drug, Byetta. The Avandia incident received widespread media attention and brought Congress to re-examine the FDA's review procedures.Yesterday, the FDA reported that the popular injectable medicine to treat type 2 diabetes, Byetta (known generically as exenatide), may be linked to cases of acute pancreatitis in some patients. Pancreatitis is an inflammation of the pancreas. Acute pancreatitis (the kind that was linked by the FDA to B... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=957304 Wed, 17 Oct 2007 14:00:00 +0100 957304 http://www.medworm.com/index.php?rid=956251&cid=t_110625_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F170795954%2F The agency reviewed 30 post-marketing reports of acute pancreatitis, which is an inflammation of the pancreas that can be fatal. After deciding an association is “suspected in some of these case,” the FDA has asked Amylin Pharmaceuticals, to revise the label. A spokeswoman for Lilly, which co-markets the diabetes med, tells Reuters the risk of pancreatitis was included in Byetta’s label late last year. “What you’re seeing today is a clarification of language to show that severe and persistent abdominal pain could be a sign of something serious like pancreatitis” and require medical attention, says Kindra Strupp. The pancreatitis cases were “rare”, she maintains, given that Byetta has been taken by 700,000 people worldwide since being approved... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=956251 Tue, 16 Oct 2007 19:53:25 +0100 956251 http://www.medworm.com/index.php?rid=918042&cid=t_110625_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2007%2F10%2Fat-last-fda-approval-of-symlin-pen.html Well, it has been promised for nearly 3 years now, but today, the company revealed that they were in receipt of an approval from the U.S. Food and Drug Administration (FDA) for the SymlinPen 60 and the SymlinPen 120 pen-injector devices for administering SYMLIN (or pramlintide acetate) injection. According to the news release, the pens are expected to be available to patients by December 2007.Patients have long complained that SYMLIN is cumbersome to use, in part, because there are no pen injection devices for the use with SYMLIN, therefore its not portable. As a result, dosing SYMLIN on the run is more cumbersome and less convenient, and may have slowed doctor and patient uptake of this insulin-adjunctive treatment approved for all forms of diabetes. The Amylin/Lilly partnership have prom... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=918042 Mon, 01 Oct 2007 13:30:00 +0100 918042 http://www.medworm.com/index.php?rid=815160&cid=t_110625_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F08%2F22%2Fspecialized-conference-for-type-1-diabetes%2F Filed under: Type 1, Childhood, Events, Opinion, Services, Allie Beatty, SupportHear ye! Hear ye! I have an announcement to make. About 3 months ago, a committee formed to explore the possibility of creating a new conference series for adults with type 1 diabetes. Most conferences are currently geared towards all types of diabetes, but a group of us felt there should be more for the unique challenges that are posed to adults living with type 1. With that in mind, we are conducting an interest study for the conference. Who would you like to see at the conference? Tell us what is missing from Type 1 diabetes (besides the obvious **cure**). This will help us with programming, as well as securing sponsorships for the event. Besides giving you all you want from the latest and greatest in type ... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=815160 Wed, 22 Aug 2007 04:00:00 +0100 815160 http://www.medworm.com/index.php?rid=528788&cid=t_110625_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2007%2F04%2Fannals-of-internal-medicine-shows.html The Annals of Internal Medicine just published a clinical trial that compared a new type of anti-diabetic drug, exenatide, (Byetta, from Eli Lilly & Co, and Amylin) an incretin mimetic, to placebo for patients already being treated for Type 2 diabetes. [Zinman B, Hoofwerf BJ, Garcia SD et al. The effect of adding exenatide to a thiazolidinedione in supoptimally controled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.] But by publishing it with an editorial that was appropriately critical of the study design and methods, and appropriately attuned to how commercial research sponsors, such as pharmaceutical companies, biotechnology companies, and device manufacturers, may manipulate how research is designed, carried out, analyzed, and reported to serve their vested in... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=528788 Sat, 07 Apr 2007 19:35:00 +0100 528788